SCHEMBL22798305

SCHEMBL22798305

CC(=O)Nc1cc(C(=O)NCCOc2ccc(C(F)(F)F)cc2)cc(C)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.56
RHOC P08134 1/20 0.51
RHOA P61586 1/20 0.51
NPC1 O15118 7/20 0.49
ADORA3 P0DMS8 1/20 0.47
CHRNB2 P17787 2/20 0.45
CHRNB4 P30926 2/20 0.45
CHRNA3 P32297 2/20 0.45
CHRNA4 P43681 2/20 0.45
RAB9A P51151 4/20 0.45
POLB P06746 2/20 0.45
CASP3 P42574 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
MAPT P10636 5/20 0.45
LMNA P02545 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22798289 0.88 SCN9A (0.54) SCN9ARHOCRHOAADORA3RAB9A
SCHEMBL22797915 0.86 SCN9A (0.53) SCN9ARHOCRHOAADORA3RAB9A
SCHEMBL22797754 0.86 NPC1 (0.46) SCN9ANPC1ADORA3CHRNB2CHRNB4
SCHEMBL30449637 0.86 NPC1 (0.46) SCN9ANPC1ADORA3CHRNB2CHRNB4
SCHEMBL20595186 0.85 SCN9A (0.52) SCN9ANPC1ADORA3RAB9APOLB
SCHEMBL22797791 0.85 SCN9A (0.61) SCN9ARHOCRHOA
SCHEMBL22797814 0.84 SCN9A (0.51) SCN9AADORA3
SCHEMBL30450047 0.84 SCN9A (0.51) SCN9AADORA3
SCHEMBL22797759 0.83 MAPT (0.48) SCN9ANPC1ADORA3RAB9APOLB
SCHEMBL20595201 0.83 SCN9A (0.46) SCN9ARHOCRHOANPC1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN claimed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP claimed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN claimed
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN disclosed
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers RAQUALIA PHARMA INC. (JP) 2021-10-26 US disclosed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP disclosed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers SCN8A, SCN7A, SCN1A SCN9A 9/4885RHOC 3105/4885RHOA 2526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.